Contrasting Baxalta (NYSE:BXLT) and Argos Therapeutics (ARGS)

Baxalta (NYSE: BXLT) and Argos Therapeutics (NASDAQ:ARGS) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.

Valuation & Earnings

This table compares Baxalta and Argos Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Baxalta N/A N/A N/A $1.19 N/A
Argos Therapeutics $950,000.00 9.31 -$53.02 million ($25.20) -0.06

Baxalta has higher earnings, but lower revenue than Argos Therapeutics. Argos Therapeutics is trading at a lower price-to-earnings ratio than Baxalta, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Baxalta and Argos Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Baxalta 9.37% 14.28% 4.62%
Argos Therapeutics -13,750.64% N/A -120.95%

Dividends

Baxalta pays an annual dividend of $0.28 per share. Argos Therapeutics does not pay a dividend. Baxalta pays out 23.5% of its earnings in the form of a dividend. Baxalta has increased its dividend for 2 consecutive years.

Analyst Recommendations

This is a summary of current recommendations for Baxalta and Argos Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Baxalta 0 0 0 0 N/A
Argos Therapeutics 0 3 0 0 2.00

Argos Therapeutics has a consensus price target of $24.00, suggesting a potential upside of 1,566.67%.

Summary

Baxalta beats Argos Therapeutics on 6 of the 8 factors compared between the two stocks.

Baxalta Company Profile

Baxalta Incorporated (Baxalta) is a biopharmaceutical company with a portfolio of differentiated therapies that seek to address medical needs across various disease areas, including hemophilia, immunology and oncology. Baxalta’s categories of products include Hemophilia products, such as Advate, Adynovate, Recombinate, Hemofil M, Immunate, Immunine, Rixubis and Prothromplex Total; Inhibitor Therapies products, including FEIBA and OBIZUR; Immunoglobulin Therapies products, which include GAMMAGARD LIQUID/KIOVIG, HYQVIA, GAMMAGARD S/D and SUBCUVIA; BioTherapeutics products, including FLEXBUMIN, BUMINATE, ARALAST NP, GLASSIA NP and CEPROTIN, and Oncology product, such as ONCASPAR. Baxalta Company develops, manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia.

Argos Therapeutics Company Profile

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

Receive News & Ratings for Baxalta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxalta and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply